IBDEI14U ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,20231,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20231,1,3,0)
 ;;=3^V45.77
 ;;^UTILITY(U,$J,358.3,20231,1,4,0)
 ;;=4^Acquired Absence of Uterus
 ;;^UTILITY(U,$J,358.3,20231,2)
 ;;=^322067
 ;;^UTILITY(U,$J,358.3,20232,0)
 ;;=233.1^^115^1224^19
 ;;^UTILITY(U,$J,358.3,20232,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20232,1,3,0)
 ;;=3^233.1
 ;;^UTILITY(U,$J,358.3,20232,1,4,0)
 ;;=4^CA in Situ (Sev. Dysplasia)
 ;;^UTILITY(U,$J,358.3,20232,2)
 ;;=^267736
 ;;^UTILITY(U,$J,358.3,20233,0)
 ;;=789.00^^115^1224^1
 ;;^UTILITY(U,$J,358.3,20233,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20233,1,3,0)
 ;;=3^789.00
 ;;^UTILITY(U,$J,358.3,20233,1,4,0)
 ;;=4^Abdom Pain, Unsp Site
 ;;^UTILITY(U,$J,358.3,20233,2)
 ;;=^303317
 ;;^UTILITY(U,$J,358.3,20234,0)
 ;;=795.09^^115^1224^2
 ;;^UTILITY(U,$J,358.3,20234,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20234,1,3,0)
 ;;=3^795.09
 ;;^UTILITY(U,$J,358.3,20234,1,4,0)
 ;;=4^Abn Pap Cervix HPV NEC
 ;;^UTILITY(U,$J,358.3,20234,2)
 ;;=^331974
 ;;^UTILITY(U,$J,358.3,20235,0)
 ;;=V45.77^^115^1224^7
 ;;^UTILITY(U,$J,358.3,20235,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20235,1,3,0)
 ;;=3^V45.77
 ;;^UTILITY(U,$J,358.3,20235,1,4,0)
 ;;=4^Acq Absence Org,Genitals
 ;;^UTILITY(U,$J,358.3,20235,2)
 ;;=^322067
 ;;^UTILITY(U,$J,358.3,20236,0)
 ;;=215.9^^115^1224^16
 ;;^UTILITY(U,$J,358.3,20236,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20236,1,3,0)
 ;;=3^215.9
 ;;^UTILITY(U,$J,358.3,20236,1,4,0)
 ;;=4^Ben Neo Soft Tissue NOS
 ;;^UTILITY(U,$J,358.3,20236,2)
 ;;=^267620
 ;;^UTILITY(U,$J,358.3,20237,0)
 ;;=221.2^^115^1224^17
 ;;^UTILITY(U,$J,358.3,20237,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20237,1,3,0)
 ;;=3^221.2
 ;;^UTILITY(U,$J,358.3,20237,1,4,0)
 ;;=4^Benign Neoplasm Vulva
 ;;^UTILITY(U,$J,358.3,20237,2)
 ;;=^267650
 ;;^UTILITY(U,$J,358.3,20238,0)
 ;;=795.05^^115^1224^20
 ;;^UTILITY(U,$J,358.3,20238,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20238,1,3,0)
 ;;=3^795.05
 ;;^UTILITY(U,$J,358.3,20238,1,4,0)
 ;;=4^Cervical (HPV) DNA POS
 ;;^UTILITY(U,$J,358.3,20238,2)
 ;;=^331573
 ;;^UTILITY(U,$J,358.3,20239,0)
 ;;=701.0^^115^1224^23
 ;;^UTILITY(U,$J,358.3,20239,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20239,1,3,0)
 ;;=3^701.0
 ;;^UTILITY(U,$J,358.3,20239,1,4,0)
 ;;=4^Circumscribe Scleroderma
 ;;^UTILITY(U,$J,358.3,20239,2)
 ;;=^108577
 ;;^UTILITY(U,$J,358.3,20240,0)
 ;;=618.01^^115^1224^29
 ;;^UTILITY(U,$J,358.3,20240,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20240,1,3,0)
 ;;=3^618.01
 ;;^UTILITY(U,$J,358.3,20240,1,4,0)
 ;;=4^Cystocele, Midline
 ;;^UTILITY(U,$J,358.3,20240,2)
 ;;=^331534
 ;;^UTILITY(U,$J,358.3,20241,0)
 ;;=621.30^^115^1224^38
 ;;^UTILITY(U,$J,358.3,20241,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20241,1,3,0)
 ;;=3^621.30
 ;;^UTILITY(U,$J,358.3,20241,1,4,0)
 ;;=4^Endometrial Hyperplas NOS
 ;;^UTILITY(U,$J,358.3,20241,2)
 ;;=^331542
 ;;^UTILITY(U,$J,358.3,20242,0)
 ;;=626.2^^115^1224^41
 ;;^UTILITY(U,$J,358.3,20242,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20242,1,3,0)
 ;;=3^626.2
 ;;^UTILITY(U,$J,358.3,20242,1,4,0)
 ;;=4^Excessive Menstrauation
 ;;^UTILITY(U,$J,358.3,20242,2)
 ;;=^75895
 ;;^UTILITY(U,$J,358.3,20243,0)
 ;;=V16.41^^115^1224^42
 ;;^UTILITY(U,$J,358.3,20243,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20243,1,3,0)
 ;;=3^V16.41
 ;;^UTILITY(U,$J,358.3,20243,1,4,0)
 ;;=4^Fam HX, Malig Neopl of Ovary
 ;;^UTILITY(U,$J,358.3,20243,2)
 ;;=^317951
 ;;^UTILITY(U,$J,358.3,20244,0)
 ;;=625.6^^115^1224^43
 ;;^UTILITY(U,$J,358.3,20244,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20244,1,3,0)
 ;;=3^625.6
 ;;^UTILITY(U,$J,358.3,20244,1,4,0)
 ;;=4^Fem Stress Incontinence
